Bengaluru, September 11 2024, Scaly India is thrilled to announce the grand opening of Sealy Gallery in Bengaluru by Continental Bedding. Located in the prestigious VRR Rise building in Koramangala, this flagship store represents a significant leap in redefining luxury sleep for the city’s discerning clientele.
The opening was led by GSS Jagannath, General Manager of Sealy India, celebrating the opening with guests and the partners of Continental Bedding. Mr Jagannath said “Mr Pavan of Continental Bedding is a long-time supporter of Sealy Posturepedic, having chosen our mattresses for his home and family to sleep on. His expertise and passion for the brand will ensure visitors to the Sealy Gallery experience personalized service and a fantastic range of products to choose from.” The spacious sleep experience space features stunning architect-designed décor and
showcases a comprehensive selection of the all-new Sealy Posturepedic collections. These combine Sealy’s world-leading technology with local craftsmanship and offer unparalleled comfort and support. “At Sealy we believe that a great night’s sleep is the foundation for your success during the day. Sealy Posturepedic represents world-leading support technology and sleep innovation. Sealy India recently opened its first manufacturing facility in Hyderabad to provide better service, with a product range tailored specifically to local consumer needs. We are proud to partner with Continental Bedding to launch this new range today,” The Sealy Gallery in Bengaluru offers a wide selection of Sealy mattresses, with prices starting at INR 55K and ranging to over 10 Lakhs. Known for blending advanced sleep science with world-class engineering, every Sealy mattress is designed to provide unrivalled comfort, support, and durability.
Sealy Posturepedic Palatial Crest models are fully imported and represent the pinnacle of luxury sleep. Sealy Posturepedic Elevate Ultra and Elevate collections are hand crafted by Sealy in India and feature Scaly’s patented support technology, premium comfort layers, and Ice Touch fabrics to help provide the healthiest, refreshing sleep. Finally, Sealy PostureSense collections offer a wide range of comfort options and are excellent value.
All areare invited to enter a world of luxury and sleep indulgence with the Sealy Gallery in Bengaluru by Continental Bedding, your sleep wellness destination. With personalized service, expert advice, and exclusive access to Sealy’s latest products, the Sealy Gallery is set to become a premier destination for those secking the superior support and comfort.
Estimated 25,000 new cases of DLBCL are diagnosed annually
In India, nearly 30-40% of people diagnosed with DLBCL do not survive for five years, which isworse than the global average 0% of all DLBCL patients relapse and face disease progression even after initial treatment.
The first FDA-approved therapy for first-line treatment of DLBCL in almost 20 years is now available in India
New treatment regimen reduce chance of the disease getting worse, relapse, or causing death by 27% compared to current treatment option
77% of patients who got the new treatment had no worsening of their disease after 2 years
As the incidence of lymphoma the most common type of blood cancer continues to rise steadily in India, the need for advanced treatment options has become increasingly urgent. Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive form of non-Hodgkin lymphoma (NHL), alone accounts for around 25,000 new cases annually in the country. Despite existing treatments, nearly 40% of DLBCL patients face relapse or disease progression, creating significant challenges for patients, their families, and the healthcare system.
However, there is renewed hope as the first FDA-approved therapy for first-line treatment of DLBCL in almost 20 years is now available in India. This breakthrough marks a pivotal milestone in the fight against DLBCL, offering patients access to cutting-edge care and the potential for improved outcomes.
Challenges in Diagnosis & Treatment Pathway
While DLBCL is a highly treatable and potentially curable form of blood cancer, mortality remains concerning, particularly in patients with returning disease (relapse/refractory).
In India, nearly 30-40% of people diagnosed with DLBCL do not survive for five years, which is worse than the global average.
A significant issue in the treatment pathway is misdiagnosis and delayed referrals by general physicians, which often result in compromised treatment efficacy.
Limited progress has been made in improving patient outcomes in previously untreated DLBCL over the last two decades. While many patients are responsive to initial treatment, as many as four in ten people do not respond to initial treatment or relapse within two years after initial treatment. These patients face limited treatment options, which adds to the emotional and psychological toll on them and their families, who live in constant fear of the disease returning.
A Breakthrough After 20 Years
For the first time in nearly two decades, there has been a groundbreaking advancement in DLBCL treatment with a new drug: Polatuzumab in combination with chemotherapy. This is the first FDA- approved therapy in nearly 20 years for the first-line treatment of DLBCL, a hard-to-treat disease and the most common form of NHL Polatuzumab is a first-in-class anti-CD79b antibody-drug conjugate (ADC).
Data from Polatuzunab trial data indicates a significant reduction of 27% in risk of progression-free survival, disease progression, relapse or death compared to the existing standard-of-care of Mab Thera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)
Since the adoption of chemotherapy in 2002, approximately 11 clinical trials have failed to demonstrate Improved clinical outcomes for DLBCL. Polatuzumab’s success is a remarkable breakthrough. Globally, over 23,000 patients have been treated in the first-line setting, and the drug is now approved in more than 90 countries, underscoring its worldwide impact.
Polatuzumab in combination with chemotherapy is now also a preferred regimen for first line treatment of DLBCL treatment under National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
Meeting Unmet Needs in DLBCL
The best chance of preventing relapse in people with DLBCL is with effective and tolerable therapy at
the time they are first diagnosed and have received no prior treatment. When subsequent therapy is needed, the course of the disease tends to have worse outcomes.
Polatuzumab, an antibody drug conjugate (ADC), offers hope for such patients by targeting specific proteins on lymphoma cells and delivering cytotoxic agents directly to the cancer cell.
Clinical data shows a 27% reduction in the risk of progression, relapse or death in patients treated with
Polatuzumab in the first line. Furthermore, 77% of patients treated with this therapy were progression- free for two years, providing a lifeline to those who previously had limited options.
Dr Amit Rauthan, Head of the Department and Consultant Medical Oncologist, Manipal Hospitals said: “In treating Diffuse Large B-Cell Lymphoma (DLBCL), providing the best possible treatment upfront can significantly improve the chances of cure with first-line therapy. Right diagnosis, proper subtyping and early initiation of advanced treatment options using monoclonal antibodies and antibody drug conjugates (ADCs) can not only enhance patient outcomes but also reduce the treatment burden in relapse settings, where salvage therapies are often costly and carry more side effects. Unfortunately, for patients in India who experience relapse or refractory (RR) DLBCL, prognosis is poor, and treatment options are limited.”
Dr Mallikarjun Kalashetty, Consultant Haematology, Haemato Oncology & Bone Marrow Transplantation, Manipal Hospital said: While blood cancers like DLBCL are highly treatable, delayed diagnosis and treatment often lead to poor outcomes for patients. Timely intervention is crucial. Innovative targeted therapies like Polatuzumab combined with chemotherapy have been a breakthrough in treatment, with clinical data showing that 77% of patients achieve two year progression free survival. This offers new hope, for a disease which has limited options after relapse or resistance to frontline therapy”
Bangalore, September 10,2024 : Transitioning between power to play, boardroom to casual is an art worth mastering. Today’s professional women look to blend their authority with style, leveraging the timeless allure of diamonds. They are more than just accessories, for closing deals or making lasting impressions natural diamonds are a statement of strength, confidence and individuality.
Natural diamonds carry a timeless appeal complementing the milestones women have achieved in their professional journey. The meticulously crafted design exemplifies sophistication paying tribute to women’s strength and achievements.
Here’s a guide to mark your presence through well-chosen accessories showcasing your personality:
Pendants & Necklaces A well-chosen elegant pendant and necklace enhance your presence without overpowering your appearance. They also offer versatility, effortlessly transitioning from formal meetings to less structured interactions, ensuring that a professional woman remains stylish and put-together throughout her day.
Forevermark Avaanti Station Necklace and, Forevermark Icon Collection Pavé and Baguette Pendant
Earrings Elegant earrings add a touch of sophistication and polish to any outfit. They can complement a tailored suit or blouse without overpowering the look, allowing women to express their personal style while maintaining a professional demeanor.
Forevermark Icon™ Collection Halo Stud Earrings and Forevermark Elements Collection Ear Studs
Bracelets Diamond bracelets offer a refined way to express personal style, whether worn solo for a subtle touch of class during meetings or stacked for a more dazzling presence at after-hours events. It serves as a versatile accessory that complements a variety of styles, the right bracelet can act as a conversation starter or a symbol of personal achievement.
These timeless pieces embody the balance of strength and grace, allowing women to transition effortlessly from the boardroom to after-hours events. As symbols of enduring power and sophistication, they serve as the perfect companions in every setting, helping to reinforce a woman’s presence and confidence.
Explore the timeless beauty of our collections. Visit the brand’s official website or find the nearest De Beers Forevermark store to shop for these exquisite pieces. To locate a store near you, click here.
For more information, please visit Forevermark.com
Bengaluru, 9th September 2024– In a case described as “one in a million,” a team of doctors at Aster Whitefield Hospital successfully treated an 8-year-old girl suffering from trichobezoar, a condition caused by trichophagia, the compulsive eating of hair also known as Rapunzel Syndrome.
It started as an innocent habit. For two years, Aditi (name changed), the young girl from Bengaluru experienced intermittent bouts of poor appetite and frequent vomiting. Her parents, puzzled by her persistent symptoms, sought help from numerous doctors, but each diagnosis and treatment failed to bring relief. Little did they know, the answer lay within their daughter’s unique and rare behavior—an answer that would lead to a rare medical condition.
The family, living in a close-knit, affluent joint household, became increasingly worried as their daughter’s condition deteriorated. Initial evaluations by paediatricians, general physicians, and ENT specialists suggested gastritis and prescribed multivitamins. It wasn’t until a month ago that the puzzle began to unravel when the girl was admitted to the Paediatric Emergency at Aster Women and Children Hospital, Whitefield, Bengaluru.
After being transferred to Aster Whitefield Hospital for further examination it was revealed that she had a trichobezoar which is basically hair mass stuck inside the gastrointestinal tract. This exceptional condition resulted from severe symptoms which are linked to trichophagia- compulsive eating of hair. The medical team led by Dr. Manjiri Somashekhar, the Lead & Senior Consultant – Paediatric Surgery, Dr. Sethu Mohan K, Senior Specialist – Pediatric surgery and Dr. Aravind A, Consultant – Paediatrics and paediatrics Intensive Care addressed this complex case.
Dr. Manjiri Somashekhar, Lead & Senior Consultant – Paediatric Surgery, Aster Women and Children Hospital, Whitefield explains, “Trichobezoar is an extremely rare condition and especially very rare in a child as young as Aditi. It is often associated with trichophagia, a psychological disorder where individuals eat hair. While commonly seen in adolescent girls, finding this in a much younger child is extraordinary and highlights the uniqueness of this case.”
Aditi underwent an open surgery to remove the hairball as it was too large and sticky to be removed endoscopically. The surgical team decided on this approach to prevent spillage into the peritoneal cavity, a choice that proved effective. The surgery lasted two and a half hours, and Aditi was hospitalized for a week for postoperative care.
“If left undiagnosed, this condition could have led to severe malnutrition, anaemia, and significant bleeding from the stomach,” Dr. Sethu Mohan K, Senior Specialist – Pediatric surgery, Aster Women and Children Hospital, Whitefield emphasized. “The hairball could have embedded into the stomach lining, causing severe bleeding during removal and potentially leading to life-threatening complications such as perforation.”
Following the surgery, Aditi was placed on a high-protein diet and partial parenteral nutrition to address her malnutrition. She also received counselling to manage her trichophagia. A child psychologist is overseeing her mental health, with her family closely involved in the treatment plan.
“The surgery was intricate and demanding,” recalled Dr. Aravind A, Consultant – Paediatrics and Paediatrics Intensive Care, Aster Women and Children Hospital, Whitefield. “But it was the only way to ensure the best outcome for our young patient.”
The child’s parents were initially shocked by the diagnosis. Extensive counselling was required to help them understand the condition and the critical nature of the treatment. Their cooperation was instrumental in early identification of symptoms and seeking appropriate medical care. The family’s vigilance and support continue to play a vital role in the child’s recovery.
The long-term prognosis for the child is positive, provided she continues to receive psychological support and regular monitoring. Preventive measures include educating parents about the signs of trichophagia, such as sparse hair in the frontal scalp area, and the importance of psychological assessment in conjunction with surgical treatment.
Tessolve receives ISO 26262 – Automotive Functional Safety Process Certification from TÜV SÜD
The certification marks a significant industry milestone for Tessolve
San Jose, California, USA, September 10, 2024: Tessolve, a leading global provider of system and silicon solutions for next-generation products, received the ISO 26262 Functional Safety Process Certification from the Certification Body of TÜV SÜD South Asia Private Limited. This prestigious certification reinforces Tessolve’s commitment to delivering high-quality, safety-compliant solutions, marking a major milestone in the company’s growing presence in the automotive semiconductor, systems, and software sectors.
TÜV SÜD, the internationally acclaimed German safety and quality expert, has granted Tessolve certification for implementing and maintaining a functional safety management system. This system ensures rigorous safety management, enhanced productivity, and improved reliability while adhering to industry standards for the functional safety of automotive electrical and electronic systems.
“Tessolve has made tremendous progress in the automotive and functional safety over the years. Achieving the ISO26262 certification is not just a milestone but a strong affirmation of the high standards and quality of work our team consistently delivers. This certification underscores our commitment to providing top-tier solutions in functional safety, ensuring that we meet and exceed industry expectations. I’m incredibly proud of our team’s dedication and expertise, which have been pivotal in reaching this achievement,” said Srini Chinamilli, Co-founder & CEO, Tessolve.
Tessolve provides comprehensive turnkey automotive semiconductor and embedded solutions, from the concept development to manufacturing, driven by a dedicated team of experts with extensive experience and knowledge in the automotive domain. By following industry standards such as ISO 26262, ASPICE, AUTOSAR and MISRA, Tessolve ensures the highest level of quality and safety in its automotive solutions. Additionally, the company actively invests in automotive R&D initiatives, to keep up with the latest trends and technologies in the market.
City Today News 
You must be logged in to post a comment.